Literature DB >> 21917526

Intravenous immunoglobulin G (IVIG) inhibits IL-1- and TNF-α-dependent, but not chemotactic-factor-stimulated, neutrophil transendothelial migration.

Andrew C Issekutz1, Derek Rowter, Heather F Macmillan.   

Abstract

High-dose intravenous immunoglobulin (IVIG) has anti-inflammatory effects via incompletely understood mechanisms. By investigating whether IVIG might modulate neutrophil (PMN) recruitment, we observed that IVIG dose-dependently inhibited (by 30-50%) PMN transendothelial migration (TEM) across human umbilical vein endothelial cells (EC) stimulated with IL-1α, IL-1β, TNF-α or IL-1β+TNF-α. Inhibition required the presence of IVIG with the responding PMNs, was attributable to the F(ab)(2) portion and was unrelated to putative contaminants in IVIG. IVIG did not inhibit IL-1β- or TNF-α-induced increase of PMN adhesion to EC, nor did it affect C5a- or IL-8-induced PMN TEM across unstimulated EC. Effects of IVIG and F(ab)(2) fragments were not associated with PMN activation, assessed by CD62L shedding, CD11b upregulation or PMN shape. Thus, IVIG selectively inhibits PMN TEM across inflammatory-cytokine-stimulated - but not unstimulated - EC, perhaps contributing to therapeutic benefit in chronic inflammation with minimal impact on chemotactic-factor-induced PMN recruitment during acute infection.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917526     DOI: 10.1016/j.clim.2011.08.003

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  5 in total

1.  Anti-IL-6 cytokine treatment has no impact on elevated hematocrit or splenomegaly in a polycythemia vera mouse model.

Authors:  Conny K Baldauf; Peter Müller; Tobias R Haage; Stephanie Adam-Frey; Juliane Lokau; Christoph Garbers; Thomas Fischer
Journal:  Blood Adv       Date:  2022-01-25

2.  Anti-inflammatory treatment in MPN: targeting TNFR1 and TNFR2 in JAK2-V617F-induced disease.

Authors:  Peter Müller; Conny K Baldauf; Tobias R Haage; Ana M Waldleben; Fabian Richter; Klaus Pfizenmaier; Thomas Fischer
Journal:  Blood Adv       Date:  2021-12-14

3.  Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease.

Authors:  Isabelle St-Amour; Mélanie Bousquet; Isabelle Paré; Janelle Drouin-Ouellet; Francesca Cicchetti; Renée Bazin; Frédéric Calon
Journal:  J Neuroinflammation       Date:  2012-10-09       Impact factor: 8.322

4.  Intravenous immunoglobulin (IVIg) provides protection against endothelial cell dysfunction and death in ischemic stroke.

Authors:  Alexander Widiapradja; Tomislav Santro; Milan Basta; Christopher G Sobey; Silvia Manzanero; Thiruma V Arumugam
Journal:  Exp Transl Stroke Med       Date:  2014-06-20

5.  Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens.

Authors:  José-María Díez; Carolina Romero; Rodrigo Gajardo
Journal:  Immunotherapy       Date:  2020-05-12       Impact factor: 4.196

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.